Does omalizumab increase the risk of malignancy? A retrospective case-control study in a single tertiary hospital-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Does omalizumab increase the risk of malignancy? A retrospective case-control study in a single tertiary hospital

Published:2024-03 Issue:1 Volume:14 Page:42-43
ISSN:2233-8276
Container-title:Asia Pacific Allergy
language:en
Short-container-title:

Author:

Kim Hyun Jee¹²,Lee Suh Young³,Cho Sang-Heon³⁴,Kang Hye-Ryun¹³⁴

Affiliation:

1. Drug Safety Center, Seoul National University Hospital, Seoul, Korea

2. Department of Pharmacy, Seoul National University Hospital, Seoul, Korea

3. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea

4. Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center, Seoul, Korea

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference4 articles.

1. Clinical data do not suggest a causal relationship between omalizumab therapy and cancer.;Fernandez;Proc Am Thorac Soc,2005

2. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab.;Long;J Allergy Clin Immunol,2014

3. Potential cancer risk with omalizumab? A disproportionality analysis of the WHO’s VigiBase pharmacovigilance database;Mota;Allergy,2021

4. Asthma and the risk of lung cancer: a meta-analysis.;Qu;Oncotarget,2017

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SAFETY OF OMALIZUMAB IN DIFFERENT PATIENT POPULATIONS;Bulletin "Biomedicine and sociology";2024-07-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP